Can repetitive transcranial magnetic stimulation be considered effective treatment option for negative symptoms of schizophrenia?

Journal of ECT

Volumn 29, Issue 1, 2013, Pages 67-74

  Prikryl, Radovan ^a   Kucerova, Hana Prikrylova ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

negative symptoms; repetitive transcranial magnetic stimulation; review; schizophrenia; treatment

Indexed keywords

AGE; AUDITORY HALLUCINATION; BLINDNESS; CLINICAL DECISION MAKING; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMAN; META ANALYSIS (TOPIC); NEGATIVE SYNDROME; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PREFRONTAL CORTEX; REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

AGE FACTORS; CEREBRAL CORTEX; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; DOUBLE-BLIND METHOD; HUMANS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 84874648606     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e318270295f     Document Type: Review

References (92)

1. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;4:51-68.
2. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;3:31-41.
3. Jockers-Scherubl MC, Bauer A, Godemann F, et al. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 2005;20:27-31.
4. Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev. 2006;4: CD005962. DOI: 10.1002/14651858.
5. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand. 2007;115:93-100.
6. Matheson SL, Green MJ, Loo C, et al. Quality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial magnetic stimulation for schizophrenia: a systematic meta-review. Schizophr Res. 2010;11:201-210.
7. Schlaepfer T, Mark G, Mayberg H, on behalf of the WFSBP Task Force on Brain Stimulation. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines on brain stimulation treatments in psychiatry. World J Biol Psychiatry. 2010;11:2-18.
8. Weinberger DR, Egan MF, Bertolino A, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry. 2001;50:825-844.
9. Hill K, Mann L, Laws KR, et al. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand. 2004;4:243-256.
10. Stoeber G, Ben-shachar D, Cardon M, et al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry. 2009;10:127-155.
11. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann NY Acad Sci. 2003;1003:138-158.
12. Bertolino A, Breier A, Callicott JH, et al. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology. 2000;22:125-132.
13. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5:267-271.
14. Jackson ME, Frost AS, Moghaddam B. Stimulation of prefrontal cortex at physiologically relevant frequencies inhibits dopamine release in the nucleus accumbens. J Neurochem. 2001;78:920-923.
15. Goldman-Rakic PS, Muly EC, Williams GV. D1 receptors in prefrontal cells and circuits. Brain Res Rev. 2001;31:295-301.
16. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-tonoise ratio in schizophrenia. Trends Neurosci. 2004;27:683-690.
17. Weinberger DR, Berman KF, Chase TN. Mesocortical dopaminergic function and human cognition. Ann NY Acad Sci. 1988;537:330-338.
18. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol. 1997;11:123-131.
19. Post RM, Kimbrell TA, Frye M. Implications of kindling and quenching for the possible frequency dependence of rTMS. CNS Spectr. 1997;2:54-60.
20. Ragert P, Dinse HR, Pleger B, et al. Combination of 5 Hz repetitive transcranial magnetic stimulation (rTMS) and tactile coactivation boosts tactile discrimination in humans. Neurosci Lett. 2003;348:105-108.
21. Knecht S, Ellger T, Breitenstein C, et al. Changing cortical excitability with low-frequency transcranial magnetic stimulation can induce sustained disruption of tactile perception. Biol Psychiatry. 2003;53:175-179.
22. D'Souza DC, Charney DS, Krystal JH. Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev. 1995;1:227-260.
23. Kole MH, Fuchs E, Ziemann U, et al. Changes in 5-HT1A and NMDA binding sites by a single rapid transcranial magnetic stimulation procedure in rats. Brain Res. 1999;826:309-312.
24. Ben-Shachar D, Gazawi H, Riboyad-Levin J, et al. Chronic repetitive transcranial magnetic stimulation alters A-adrenergic and 5-HT2 receptor characteristics in rat brain. Brain Res. 1999;816:78-83.
25. Taber MT, Fibiger HC. Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors. J Neurosci. 1995;15:3896-3904.
26. Keck M, Welt T, Muller M, et al. Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology. 2002;43:101.
27. Strafella AP, Paus T, Barrett J, et al. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci. 2001;21:RC157.
28. Strafella AP, Paus T, Fraraccio M, et al. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain. 2003;126:2609-2615.
29. Jin Y, Potkin SG, Kemp AS, et al. Therapeutic effects of individualized frequency transcranial magnetic stimulation (rTMS) on the negative symptoms of schizophrenia. Schizophr Bull. 2006;32:556-561.
30. Fox P, Ingham R, George MS, et al. Imaging human intra-cerebral connectivity by PET during TMS. Neuroreport. 1997;8:2787-2791.
31. Conca A, Peschina W, Konig P, et al. Effect of chronic repetitive transcranial magnetic stimulation on regional cerebral blood flow and regional cerebral glucose uptake in drug treatment resistant depressives: a brief report. Neuropsychobiology. 2002;45:27-31.
32. Mottaghy FM, Keller CE, Gangitano M, et al. Correlation of cerebral blood flow and treatment effects of repetitive transcranial magnetic stimulation in depressed patients. Psychiatry Res. 2002;115:1-14.
33. Geller V, Grisaru N, Abarbanel JM, et al. Slow magnetic stimulation of prefrontal cortex in depression and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21:105-110.
34. Feinsod M, Kreanin B, Chistyakov A, et al. Preliminary evidence for beneficial effect of low-frequency repetitive transcranial magnetic stimulation in patients with major depression and schizophrenia. Depress Anxiety. 1998;7:65-68.
35. Cohen E, Bernardo M, Misana J, et al. Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study. J Neurol Neurosurg Psychiatry. 1999;67:129-130.
36. Jandl M, Bettner R, Sack A, et al. Changes in negative symptoms and EEG in schizophrenic patients after repetitive transcranial magnetic stimulation (rTMS): an open-label pilot study. J Neural Transm. 2005;112:955.
37. Sachdev P, Loo C, Mitchell P, et al. Transcranial magnetic stimulation for the deficit syndrome of schizophrenia: a pilot investigation. Psychiatry Clin Neurosci. 2005;29:354-357.
38. Sachdev PS. Transcranial magnetic stimulation for the deficit syndrome of schizophrenia. Acta Neuropsychiatrica. 2007;19:56-58.
39. Klein E, Kolsky Y, Puyerovsky M, et al. Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham-controlled pilot study. Biol Psychiatry. 1999;46:1451-1454.
40. Hajak G, Marienhagen J, Langguth B, et al. High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. Psychol Med. 2004;34:1157-1163.
41. Holi MM, Eronen M, Toivonen K, et al. Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophr Bull. 2004;30:429-434.
42. Goyal N, Nizamie SH, Desarkar P. Efficacy of adjuvant high frequency repetitive transcranial magnetic stimulation on negative and positive symptoms of schizophrenia: preliminary results of a double blind sham-controlled study. J Neuropsychiatry Clin Neurosci. 2007;19:464-467.
43. Mogg A, Purvis R, Eranti S, et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. Schizophr Res. 2007;93:221-228.
44. Novak T, Horacek J, Mohr P, et al. The double-blind sham-controlled study of high-frequency rTMS (20 Hz) for negative symptoms in schizophrenia. Negative results. Neuro Endocrinol Lett. 2006;25:209-213.
45. Prikryl R, Kasparek T, Skotakova S, et al. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study. Schizophr Res. 2007;95:151-157.
46. Fitzgerald PB, Herciny S, Hoy K, et al. A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation. 2008;1:27-32.
47. Schneider AL, Schneider TL, Stark H. Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: a 4-week randomized placebo controlled study. Brain Stimulation. 2008;1:106-111.
48. Nahas Z, McConnell KCS, Molloy M, et al. Could left prefrontal rTMS modify negative symptoms and attention in schizophrenia? Biol Psychiatry. 1999;45:37.
49. Rollnik JD, Huber TJ, Mogg H, et al. High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients. Neuroreport. 2000;11:4013-4015.
50. Stevens JR, Livermore A. Telemetered EEG in schizophrenia: spectral analysis during abnormal behavior episodes. J Neurol Neurosurg Psychiatry. 1982;45:385-395.
51. Colombo C, Gambini O, Macciardi F, et al. Alpha reactivity in schizophrenia and in schizophrenic spectrum disorders: demographic clinical and hemispheric assessment. Int J Psychophysiol. 1989;7:47-54.
52. Hoffman R, Buchsbaum M, Escobar M, et al. EEG coherence of prefrontal areas in normal and schizophrenia males during perceptual activation. J Neuropsychiatry Clin Neurosci. 1991;3:169-175.
53. Klemm E, Danos P, Grunwald F, et al. Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depressionVa study with single proton emission computed tomography. Psychiatry Res. 1996;69:1-10.
54. Wolkin A, Sanfilipo M, Wolf AP, et al. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry. 1992;49:959-965.
55. Sabri O, Erkwoh R, Schreckenberger M, et al. Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. J Nucl Med. 1997;8:181-188.
56. Cordes J, Thunker J, Agelink MW, et al. Effects of 10 Hz repetitive transcranial magnetic stimulation (rTMS) on clinical global impression in chronic schizophrenia. Psychol Res. 2010;177:32-36.
57. Mittrach M, Thunker J, Winterer G, et al. The tolerability of rTMS treatment in schizophrenia with respect to cognitive function. Pharmacopsychiatry. 2010;43:110-117.
58. Freitas C, Fregni F, Pascual-Leon A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr Res. 2009;108:11-24.
59. Dlabac-de Lange JJ, Knegtering R, Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J Clin Psychiatry. 2010;71:411-419.
60. Stanford AD, Sharif Z, Corcoran C, et al. rTMS strategies for the study and treatment of schizophrenia: a review. Int J Neuropsychopharmacol. 2008;11:563-576.
61. George MS, Padberg F, Schlaepfer TE, et al. Controversy: repetitive transcranial magnetic stimulation or transcranial direct current stimulation shows efficacy in treating psychiatric diseases (depression, mania, schizophrenia, obsessive-compulsive disorder, panic, posttraumatic stress disorder). Brain Stimulation. 2009;2:14-21.
62. Kirkpatrick B, Conley RC, Kakoyannis A, et al. Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: an unbiased cell-counting study. Synapse. 1999;34:95-102.
63. Kirkpatrick B, Buchanan RW, Ross DE, et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165-171.
64. Kay SR, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
65. Brebion G, Amador X, Smith M, et al. Depression, psychomotor retardation, negative symptoms, and memory in schizophrenia. Neuropsychology, Neuropsychiatry, and Behavioral Neurology. 2000;13:177-183.
66. Nakaya M, Ohmori K, Komahashi T, et al. Depressive symptoms in acute schizophrenic inpatients. Schizophr Res. 1997;25:131-139.
67. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39:784-788.
68. McKenna PJ, Lund CE, Mortimer AM. Negative symptoms: relationship to other schizophrenic symptom classes. Br J Psychiatry. 1987;104-107.
69. Sax KW, Strakowski SM, Keck PE Jr, et al. Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Br J Psychiatry. 1996;168:68-71.
70. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry. 1999;45:17-25.
71. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
72. Hoffman R, Hampson M, Wu K, et al. Probing the pathophysiology of auditory/verbal hallucinations by combining functional magnetic resonance imaging and transcranial magnetic stimulation. Cereb Cortex. 2007;17:2733-2743.
73. Herwig U, Padberg F, Unger J, et al. Transcranial magnetic stimulation in therapy studies: examination of the reliability of "standard" coil positioning by neuronavigation. Biol Psychiatry. 2001;50:58-61.
74. Schonfeldt-Lecuona C, Gron G, Walter H, et al. Stereotaxic rTMS for the treatment of auditory hallucinations in schizophrenia. Neuroreport. 2004;15:1669-1673.
75. Langguth B, Eichhammer P, Zowe M, et al. Neuronavigated transcranial magnetic stimulation and auditory hallucinations in a schizophrenic patient: monitoring of neurobiological effects. Schizophr Res. 2006;84:185-186.
76. Horacek J, Brunovsky M, Novak T, et al. Effect of low-frequency rTMS on electromagnetic tomography (LORETA) and regional brain metabolism (PET). in schizophrenia patients with auditory hallucinations. Neuropsychobiology. 2007;55:132-142.
77. Koutsouleris N, Gaser C, Jäger M, et al. Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel based morphometric study. Neuroimage. 2008;39:1600-1612.
78. Fujimoto T, Takeuch K, Matsumoto T, et al. Abnormal glucose metabolism in the anterior cingulate cortex in patients with schizophrenia. Psychiatry Res. 2007;154:49-58.
79. Zetzsche T, Preuss UW, Frodl T, et al. White matter alterations in schizophrenic patients with pronounced negative symptomatology and with positive family history for schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2008;258:278-284.
80. Torrey EF. Schizophrenia and the inferior parietal lobule. Schizophr Res. 2007;97:215-225.
81. Andreasen NC, Pierson R. The role of the cerebellum in schizophrenia. Biol Psychiatry. 2008;64:81-88.
82. Prikryl R, Ustohal L, Prikrylova Kucerova H, et al. Effect of sequential frontotemporal repetitive transcranial magnetic stimulation (rTMS) on schizophrenia. Activitas Nervosa Superior Rediviva. 2010;1:37-41.
83. Nahas Z, Li X, Kozel FA, et al. Safety and benefits of distance-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55-75 years of age: a pilot study. Depress Anxiety. 2004;19:249-256.
84. Sanfilipo M, Lafargue T, Rusinek H, et al. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry. 2000;57:471-480.
85. Kozel FA, Nahas Z, deBrux C, et al. How coil-cortex distance relates to age, motor threshold, and antidepressant response to repetitive transcranial magnetic stimulation. J Neuropsychiatry Clin Neurosci. 2000;12:376-384.
86. Stokes MG, Chambers CD, Gould IC, et al. Simple metric for scaling motor threshold based on scalp-cortex distance: application to studies using transcranial magnetic stimulation. J Neurophysiol. 2005;94:4520-4527.
87. Loo CK, Taylor JL, Gandevia SC, et al. Transcranial magnetic stimulation (TMS) in controlled treatment studies: are some "sham" forms active? Biol Psychiatry. 2000;47:325-331.
88. Lisanby SH, Gutman D, Luber B, et al. Sham TMS intracerebral measurement of the induced electrical field and the induction of motor-evoked potentials. Biol Psychiatry. 2001;49:460-463.
89. Arana AB, Borckardt JJ, Ricci R, et al. Electrical stimulation as a sham control for rTMS: does it truly mimic the cutaneous sensation and pain of active prefrontal rTMS? Brain Stimulation. 2008;1:4-51.
90. Borckardt J, Walker J, Branham RK, et al. Development and evaluation of a portable sham tms system. Brain Stimulation. 2008;1:52-59.
91. O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multi-site randomized controlled trial. Biol Psychiatry. 2007;62:1208-1216.
92. Lieberman JA, Stroup S, McEvoy JP, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.